Patents Examined by Allison M Fox
-
Patent number: 11976297Abstract: The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors, that exhibit cross-talk between the receptors.Type: GrantFiled: September 21, 2021Date of Patent: May 7, 2024Assignee: A2 BIOTHERAPEUTICS, INC.Inventor: Alexander Kamb
-
Patent number: 11975068Abstract: The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.Type: GrantFiled: February 2, 2017Date of Patent: May 7, 2024Assignee: LONGEVERON, INC.Inventors: Joshua M. Hare, Ana Marie Landin
-
Patent number: 11976278Abstract: Described herein are recruitment methods and compounds, compositions, and systems for recruitment. Also described herein are methods and compositions for template editing of genomic DNA using Agrobacterium-derived T-DNA molecules and/or proteins.Type: GrantFiled: December 6, 2020Date of Patent: May 7, 2024Assignee: Pairwise Plants Services, Inc.Inventors: Aaron Hummel, Shai Joshua Lawit, Jingyi Nie, Sabine Fräbel, Sharon Leigh Guffy
-
Patent number: 11975026Abstract: The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and/or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and/or CD19, methods of making a cell comprising the same and vectors encoding the same.Type: GrantFiled: November 25, 2020Date of Patent: May 7, 2024Assignee: Novartis AGInventors: Boris Engels, Carla Patricia Guimaraes
-
Patent number: 11970713Abstract: The invention relates to a method for long-term ex vivo maintenance or expansion of one or more of a human erythroblast, a human megakaryocyte-erythroid progenitor, or a human common myeloid progenitor, comprising the step of: culturing cells comprising one or more of those cells in a culture medium comprising one or more selected from a tankyrase inhibitor, a growth factor, a B-Raf kinase inhibitor and a GSK-3 inhibitor.Type: GrantFiled: December 2, 2021Date of Patent: April 30, 2024Assignee: OCGENE THERAPEUTICS CORPORATIONInventors: Chang Tong, Yibin Lin, Kangtao Lv
-
Patent number: 11965180Abstract: Provided is a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. A human cancer tissue was repeatedly grown in a NOG mouse, separated cancer cells from the grown cancer tissue, and tested and compared various cancer cell culture processes. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process.Type: GrantFiled: August 14, 2020Date of Patent: April 23, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Patent number: 11963990Abstract: The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.Type: GrantFiled: May 24, 2023Date of Patent: April 23, 2024Assignee: KaliVir Immunotherapeutics, Inc.Inventors: Stephen Howard Thorne, Mingrui Zhang
-
Patent number: 11965190Abstract: Provided herein are a vector, a genetically modified bacterium including the vector, methods of making the bacterium, methods of using the bacterium, and kits including the bacterium. The vector includes a coding region encoding at least one antimicrobial peptide, and the antimicrobial peptide includes at least one lysin.Type: GrantFiled: September 7, 2018Date of Patent: April 23, 2024Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Yiannis John Kaznessis, Seth Ritter, Benjamin Hackel
-
Patent number: 11957720Abstract: The present invention generally relates to the field of probiotic bacteria. In particular, it relates to methods for treating or preventing functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.Type: GrantFiled: April 27, 2022Date of Patent: April 16, 2024Assignee: Societe des Produits Nestle S.A.Inventors: Peter McLean, Gabriela Bergonzelli Degonda, Stephen Michael Collins, Premysl Bercik, Elena Verdu de Bercik
-
Patent number: 11959120Abstract: Provided herein are methods of producing oils with reduced saturated fatty acids. The methods include culturing oil-producing microorganisms in a fermentation medium in the presence of one or more antifoaming agents under a controlled carbon consumption rate, wherein the culturing produces oils comprising fatty acids and wherein less than 35% of the fatty acids in the oil are saturated fatty acids.Type: GrantFiled: October 28, 2020Date of Patent: April 16, 2024Assignee: MARA Renewables CorporationInventors: Zhiyong Sun, Alan Sothern, Kevin Berryman, Mercia Valentine, Michael Milway, Laura Purdue, Roberto E. Armenta
-
Patent number: 11957718Abstract: The invention provides compositions comprising multipotent progenitor cells isolated from tonsillar tissue and differentiated cells derived therefrom and methods for using the cells for the treatment of diseases or disorders.Type: GrantFiled: December 22, 2017Date of Patent: April 16, 2024Assignee: University of Maryland, BaltimoreInventors: Michal Zalzman, Rodney Taylor
-
Patent number: 11952605Abstract: The present invention relates to methods of modulating the mannose content of recombinant proteins.Type: GrantFiled: February 22, 2023Date of Patent: April 9, 2024Assignee: Amgen Inc.Inventors: Jian Wu, Sean Davern, Simina Crina Petrovan, Michael Charles Brandenstein, Katherine Rose Lindahl, Shawn Erik Lillie
-
Patent number: 11951131Abstract: Provided are chimeric antigen receptors (CARs) having antigenic specificity for B-cell Maturation Antigen (SLAMF7). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.Type: GrantFiled: June 26, 2019Date of Patent: April 9, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: James N. Kochenderfer, Steven A. Feldman
-
Patent number: 11951138Abstract: A method of mimicking a phenotype of a first ruminating animal in a second ruminating animal is disclosed. The method comprises administering to the second ruminating animal a microbial composition comprising a plurality of microbes having a signature which is statistically significantly similar to the microbial signature of a rumen microbiome of the first ruminating animal, wherein the first and the second ruminating animal are of identical species, thereby mimicking the phenotype of the first ruminating animal in the second ruminating animal.Type: GrantFiled: March 13, 2014Date of Patent: April 9, 2024Assignee: The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center)Inventors: Itzhak Mizrahi, Elie Jami
-
Patent number: 11944647Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: GrantFiled: June 22, 2022Date of Patent: April 2, 2024Assignee: Juno Therapeutics, Inc.Inventors: Tina Albertson, Brian Christin, Jacob Randolph Garcia, Christopher Glen Ramsborg, Claire L. Sutherland, Clinton Weber, Rachel K. Yost, Mark J. Gilbert, He Li
-
Patent number: 11946070Abstract: The present invention relates to a medium composition for reinforcing the efficacy of stem cells, including ethionamide, a method of reinforcing the efficacy of stem cells, including culturing stem cells in the medium composition, a method of preparing stem cells with reinforced efficacy, stem cells prepared by the above-mentioned method, and a use thereof. According to the present invention, the anti-inflammatory effect of mesenchymal stem cells and expression levels of paracrine factors may be effectively improved by a simple method of treating mesenchymal stem cells with ethionamide, and the stem cells obtained by the above method may be effectively used for preventing or treating an inflammatory disease or a degenerative brain disease.Type: GrantFiled: July 15, 2020Date of Patent: April 2, 2024Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Duk Lyul Na, Jong Wook Chang, Hyo Jin Son
-
Patent number: 11944718Abstract: The disclosure herein relates to isolated and purified mammalian fetal allografts and kits and compositions containing these. Also disclosed are methods of preparing isolated and purified mammalian fetal allografts; methods of contacting a wound of a subject with these, and methods of treating a disease or condition with these.Type: GrantFiled: December 16, 2022Date of Patent: April 2, 2024Assignee: Healthtech Solutions, Inc.Inventors: Bradley Robinson, Douglas Ivins Schmid, Thayne Sherman Ekness
-
Patent number: 11939593Abstract: Compositions and methods for improving embryo development, treating idiopathic male factor infertility, and enabling infertile/sub-fertile/sterile men to father their own genetic offspring are provided. Typically, the methods include administering into a male or female gamete or fertilized embryo an effective amount of a compound that increases bioavailability of a TET protein to improve development of an embryo resulting from fertilization of the female gamete by a male gamete. The compound can be administered into the gamete or embryo before, during, or after fertilization. The compound can be administered by an injection such as intracytoplasmic injection. The compound and the male gamete can be administered in combination by intracytoplasmic sperm injection. Methods of making male gametes, and methods of modifying the genome of a male gamete or embryo using an effective amount of a gene editing composition to correct a gene mutation or anomaly in the genome thereof are also provided.Type: GrantFiled: August 1, 2019Date of Patent: March 26, 2024Assignees: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., EMORY UNIVERSITYInventors: Charles A. Easley, IV, Anthony W. S. Chan
-
Patent number: 11931401Abstract: In the present invention, it was confirmed that the modified protein in which the 356th serine of Runx3 is substituted with alanine has an increased activity of maintaining the complex with Brd2 by more than 10 times compared to the wild-type Runx3, and the apoptosis effect is improved in various cancer cell lines compared to the wild-type Runx3. Therefore, the modified protein in which the 356th serine of Runx3 is substituted with an amino acid that cannot be phosphorylated by a kinase of the present invention, the polynucleotide coding thereof, the vector carrying the polynucleotide, or the virus or cell transformed with the vector can be used as a therapeutic agent for various cancers.Type: GrantFiled: April 23, 2021Date of Patent: March 19, 2024Assignee: GeneCraft Inc.Inventors: Suk Chul Bae, Jung Won Lee, You Soub Lee
-
Patent number: 11930824Abstract: The present algae extracts are used for biocontrol of insects. Specifically, the present extracts are obtained from Cystoseria muricatum using a polysolvent system. Once obtained, the extracts can be applied to plants to repel insects and/or to facilitate fertilization of the plants.Type: GrantFiled: March 22, 2023Date of Patent: March 19, 2024Assignee: KING FAISAL UNIVERSITYInventor: Nermin Adel El Semary